AstraZeneca PLC (NASDAQ:AZN) Q4 2023 Earnings Conference Call February 8, 2024 6:45 AM ET Company Participants Andy Barnett - Head, IR Pascal Soriot - CEO Aradhana Sarin - CFO David Fredrickson - EVP, Oncology Business Susan Galbraith - EVP, Oncology R&D Ruud Dobber - EVP, BioPharmaceuticals Business Sharon Barr - EVP, BioPharmaceuticals R&D Marc Dunoyer - CEO, Alexion Iskra Reic - EVP of Vaccines & Immune Therapies Conference Call Participants James Gordon - JP Morgan Emily Field - Barclays Matthew Weston ...

Key TakeawaysAstraZeneca PLC missed profit forecasts Thursday as its fourth-quarter sales were slowed by falling demand for COVID-19 vaccines and medicines.The drug maker's revenue was also negatively affected by generic competition in Japan for its Nexium acid reflux treatment.AstraZeneca's American Depositary Receipts (ADRs) dropped to their lowest level in 16 months after the earnings were released Thursday.AstraZeneca PLC's (AZN) American depositary receipts (ADRs) fell more than 4% Thursday after the d ...

This being Thursday morning, we see new Weekly Jobless Claims data ahead of the opening bell for trading. Initial Jobless Claims came in 2000 lower than projections to 218K, down 9K claims from the upwardly revised 227K posted the previous week. This is yet another sub-220K week, which we were routinely above from about March through early September of last year, but this remains consistent with an overall healthy labor market.Continuing Claims had more recently been drawing closer scrutiny, as last week’s ...

This being Thursday morning, we see new Weekly Jobless Claims data ahead of the opening bell for trading. Initial Jobless Claims came in 2000 lower than projections to 218K, down 9K claims from the upwardly revised 227K posted the previous week. This is yet another sub-220K week, which we were routinely above from about March through early September of last year, but this remains consistent with an overall healthy labor market.Continuing Claims had more recently been drawing closer scrutiny, as last week’s ...

Full Year and Q4 2023 Results Conference call and webcast for investors and analysts Forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter ‘the Group’) provides the following cautionary statement: This document contains certain forward-looking statem ...

FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2024 Commission File Number: 001-11960 AstraZeneca PLC 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F X Form 40-F __ Indicate by check mark if the registra ...

AstraZeneca PLC (LSE:AZN) shares fell 1.8%, wiping £2.8 billion from the value of the business, as lingering concerns on the drug maker's cost base overshadowed better than expected results and strong forward guidance. Shore Capital is hoping management can dispell these worries: "We sense there had been an element of uncertainty heading into results around how quickly the cost base could continue to evolve over the near-medium term and expect some further clarity might be provided around this during the ca ...

CAMBRIDGE, United Kingdom--(BUSINESS WIRE)--AstraZeneca: Revenue and EPS summary     FY 2023 Q4 2023       % Change   % Change $m Actual   CER1   $m Actual CER - Product Sales 43,789 2   4   11,323 5 5 - Alliance Revenue2   1,428 89   89   424 69 67 - Collaboration Revenue2 <td colspan="1" row ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca is investing $300 million in a state-of-the-art facility in Rockville, MD to launch its life-saving cell therapy platforms in the US for critical cancer trials and future commercial supply. More than 150 new highly skilled jobs will be created to initially focus on manufacturing T-cell therapies to enable clinical trials to be conducted around the world. Over time, the site may expand its focus to support other disease areas. The site represents the latest inv ...

Artificial intelligence grabbed most of the headlines last year, but weight loss stocks were equally noteworthy. It grew slowly for several years but really went stratospheric last year.The wider availability of Ozempic and Wegovy set the world on fire. A class of drugs known as glycogen-like peptide-1 (GLP-1) therapies for diabetes and obesity, demand was fueled by celebrities and social media influencers touting their slimming effects. They also spurred further investment into weight-loss-in-a-pill becaus ...